RN-tre CRISPR Activation Plasmid (h): sc-411321-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- RN-tre CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- RN-tre CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by RN-tre CRISPR Activation Plasmid (h) and RN-tre CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the USP6NL transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RN-tre CRISPR Activation Plasmid (h) | sc-411321-ACT | 20 µg | $397.00 |
USP6NL (RN-tre) encodes a Rab GTPase-activating protein implicated in regulation of endocytic trafficking and receptor recycling, linking membrane transport to growth factor receptor signaling dynamics. By modulating Rab-dependent vesicle maturation and sorting, RN-tre can influence spatial and temporal control of pathways such as EGFR/MAPK signaling and cytoskeletal remodeling that govern cell migration and invasion. Altered USP6NL expression has been reported in multiple tumor contexts and is studied as a determinant of receptor trafficking programs that reshape proliferative and motility phenotypes. As a human trafficking regulator, it is also relevant for dissecting how membrane transport intersects with signal transduction, adhesion turnover, and cellular stress responses.
RN-tre CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous USP6NL expression without altering the underlying DNA sequence.
RN-tre CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the USP6NL locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the USP6NL transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous RN-tre expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native USP6NL locus and enabling the study of RN-tre-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of RN-tre pathway restoration in tumor cells with silenced or reduced USP6NL expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.